OABI.US OmniAb Inc.

Healthcare Biotechnology USA Stocks
4.89 USD
Close of Nov 16, 2026
1.35 5.45
Market cap
USD 713M
P/E
-
P/B
2.87x
ROE
-15.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OABI.US undervalued?

Graham number

The Graham number of OmniAb Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OmniAb Inc. fundamental analysis

No fundamental analysis for OmniAb Inc. yet.

OmniAb Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OmniAb Inc.

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powe…

Full company profile